KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Current Taxes (2016 - 2024)

Edwards Lifesciences (EW) has 15 years of Current Taxes data on record, last reported at $1.3 million in Q4 2024.

  • For Q4 2024, Current Taxes fell 98.39% year-over-year to $1.3 million; the TTM value through Dec 2024 reached $1.3 million, down 98.39%, while the annual FY2024 figure was $1.3 million, 98.39% down from the prior year.
  • Current Taxes reached $1.3 million in Q4 2024 per EW's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Current Taxes topped out at $239.3 million in Q1 2020 and bottomed at $1.1 million in Q2 2024.
  • Average Current Taxes over 5 years is $137.9 million, with a median of $143.4 million recorded in 2022.
  • Peak YoY movement for Current Taxes: decreased 7.75% in 2020, then plummeted 98.65% in 2024.
  • A 5-year view of Current Taxes shows it stood at $215.3 million in 2020, then fell by 11.75% to $190.0 million in 2021, then decreased by 24.53% to $143.4 million in 2022, then tumbled by 43.79% to $80.6 million in 2023, then crashed by 98.39% to $1.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Current Taxes were $1.3 million in Q4 2024, $1.1 million in Q3 2024, and $1.1 million in Q2 2024.